March 28, 2024, Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. (hereinafter referred to as "NKF) received the approval letter of Enoxaparin sodium injection fromEgyptian Drug Authority, the product officially launched in  the market.

Thromboembolic diseases are the leading cause of morbidity and mortality worldwide . Enoxaparin Sodium injection, as the gold standard drug, is currently the most effective and clinically used anticoagulant in the world. Founded in 1987, NKF has been committed to providing high-quality, safe and effective drugs and services to patients worldwide for more than 30 years. The data shows that the global market size of Enoxaparin Sodium is about 3.77 billion USDs in 2023, and Egyptian is about 52.02 million USD.

 Egypt is the largest market with high  regulatory standards in the north of Africa. After two years, NKF broke the deadlock in reference drug controling whole market and successfully entered the Egyptian pharmaceutical market, which brought a new growth point for the global market layout of NKF.